Study ID: Seattle Genetics SGN228-001 Advanced Solid Tumor Study


A phase 1 study of SGN-CD228A in select advanced solid tumors

Description: This is an early phase clinical trial (Phase I) of a drug called SGN-CD228A. This study is designed to study the effect of an investigational drug, SGN-CD228A. Research data from animal studies suggests that SGN-CD228A can destroy cancer cells and stabilize disease in various cancers. The main purposes of this study are to: • Find out if SGN-CD228A is safe for people and what the possible side effects are. • Find out if SGN-CD228A works to treat solid tumors. This study is designed for patients with 1 of the 6 tumor types targeted for initial clinical evaluation 1. Metastatic cutaneous melanoma, 2. Malignant pleural mesothelioma 3. [MPM], human epidermal growth factor receptor 2-negative metastatic breast cancer [HER2– mBC] 4. Advanced non-small cell lung cancer [NSCLC] 5. Metastatic colorectal cancer [mCRC] 6. Advanced pancreatic ductal adenocarcinoma [PDAC]) To be elgible for the study you must: • Be >18 years of age • Have one of the 6 targeted tumor types • You must have relapsed, refractory, or progressive disease with no appropriate standard of therapy available. • You must have measureable disease
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Solid Tumors
Phase I
Active - Open to Accrual